OmniAb to Participate in Two Investor Conferences in November

Rhea-AI Summary

OmniAb (NASDAQ: OABI) announced its participation in two major investor conferences in November. The company will attend the Stifel 2024 Healthcare Conference at the Lotte New York Palace Hotel on November 18-19, where CFO Kurt Gustafson will conduct one-on-one investor meetings. Additionally, CEO Matt Foehr will participate in the Jefferies London Healthcare Conference at the Waldorf Hilton from November 19-21, engaging in one-on-one and small-group investor meetings.

EMERYVILLE, Calif.--(BUSINESS WIRE)-- OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in two investor conferences during the month of November.

• Stifel 2024 Healthcare Conference, November 18-19 at the Lotte New York Palace Hotel. Kurt Gustafson, Chief Financial Officer, will participate in one-on-one meetings with investors on Tuesday, November 19^th.

• Jefferies London Healthcare Conference, November 19-21 at the Waldorf Hilton. Matt Foehr, Chief Executive Officer, will participate in one-on-one and small-group meetings with investors on November 19-20.

About OmniAb^®

OmniAb licenses cutting edge discovery research technology to the pharmaceutical and biotech industry to enable the discovery of next-generation therapeutics. Our technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for our partners’ drug development efforts. At the heart of the OmniAb platform is something we call Biological Intelligence™ (BI), which powers the immune systems of our proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.

We believe the OmniAb animals comprise the most diverse host systems available in the industry. Our suite of technologies and methods, including computational antigen design and immunization methods, paired with high-throughput single B cell phenotypic screening and mining of next-generation sequencing datasets with custom algorithms, are used to identify fully-human antibodies with exceptional performance and developability characteristics.

Our proprietary transgenic animals, including OmniRat^®, OmniChicken^® and OmniMouse^® have been genetically modified to generate antibodies with human sequences to streamline the development of human therapeutic candidates. OmniFlic^® and OmniClic^® are fixed or common light-chain rats and chickens, respectively, designed to facilitate the discovery of bispecific antibodies. OmniTaur™ provides cow-inspired antibodies with unique structural characteristics for challenging targets. OmnidAb™, is an in vivo platform for the discovery of single domain antibodies based upon a human VH scaffold that affinity matures in a chicken host environment to provide a functionally diverse immune repertoire unavailable from mammalian systems. Our proprietary technologies are joined with and leverage OmniDeep™, which is a suite of in silico, AI and machine learning tools for therapeutic discovery and optimization that are woven throughout our various technologies and capabilities. Additionally, an established core competency focused on ion channels and transporters further differentiates OmniAb’s technology and creates opportunities in many important and emerging target classes.

OmniAb technologies can be leveraged for the discovery of a variety of next-generation antibody-based therapeutic modalities, including bi- and multi-specific biologics, antibody-drug conjugates, CAR-T therapies, targeted radiotherapeutics, and many others.

For more information, please visit www.omniab.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241030117295/en/

OmniAb, Inc.

Neha Singh, Ph.D.

investors@OmniAb.com

X @OmniAbTech

(510) 768-7760

Source: OmniAb, Inc.

FAQ

Which investor conferences will OmniAb (OABI) attend in November 2024?

OmniAb will participate in the Stifel 2024 Healthcare Conference (November 18-19) and the Jefferies London Healthcare Conference (November 19-21).

Where will the Stifel 2024 Healthcare Conference for OmniAb (OABI) take place?

The Stifel 2024 Healthcare Conference will take place at the Lotte New York Palace Hotel.

Who will represent OmniAb (OABI) at the Jefferies London Healthcare Conference?

Matt Foehr, CEO of OmniAb, will represent the company at the Jefferies London Healthcare Conference.

What type of meetings will OmniAb (OABI) conduct at these conferences?

At Stifel, they will conduct one-on-one meetings, while at Jefferies, they will hold both one-on-one and small-group meetings with investors.